Composting rapidly reduces levels of extractable oxytetracycline in manure from therapeutically treated beef calves.

Oxytetracycline (OTC) is a broad-spectrum antibiotic used in livestock production. The widespread use and relative persistence of OTC may encourage development of antibiotic-resistant bacteria. The objective of this study was to determine whether composting would substantially reduce the concentration of OTC found in manure from medicated animals. The effect of OTC on composting was also investigated. Five beef calves were medicated for 5 days with 22 mg/kg/day of OTC. Approximately 23% of the OTC fed to the calves was recovered in the manure. Manure samples collected from calves prior to and after medication were mixed with straw and woodchips, and aliquots of the subsequent mixtures were treated in laboratory composters for 35 days. In addition, aliquots of the OTC-containing mixture were incubated at 25 degrees C or sterilized followed by incubation at 25 degrees C. The presence of OTC did not appear to affect composting processes. Within the first six days of composting, levels of extractable OTC in the compost mixture decreased from 115+/-8 microg/g dry weight to less than 6+/-1 microg/g dry weight (a 95% reduction). In contrast, levels of extractable OTC in room temperature incubated and sterilized mixtures decreased only 12-25% after 37 and 35 days, respectively. Levels of total heterotrophic bacteria and OTC-resistant bacteria in the finished compost mixture were roughly 30-fold higher and 10-fold lower, respectively, than levels in the mixture prior to composting. Although the basis of the OTC disappearance during composting is not known, the preponderence of OTC-sensitive bacteria and the decrease of OTC-resistant bacteria in the finished compost suggests that OTC residues have been rendered biologically inactive or unavailable.

Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial.

PURPOSE: To describe the complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis. METHODS: Prospective data collection within the context of a randomized, controlled clinical trial, comparing a regimen of the ganciclovir implant plus oral ganciclovir to one of intravenous cidofovir for the treatment of cytomegalovirus retinitis in patients with AIDS. Adverse events were compared for patients undergoing implant surgery in the following groups: primary versus replacement implant surgery, inpatient versus outpatient surgery, and general versus local anesthesia. RESULTS: Fifty-six eyes of 42 patients underwent a total of 74 ganciclovir implant surgeries. Vitreous hemorrhage was the most common adverse event, occurring in 10% of eyes undergoing surgery with local anesthesia but in no eyes undergoing surgery with general anesthesia. All vitreous hemorrhages resolved within 60 days. Patients in the general anesthesia and inpatient surgery groups tended to have a lower risk of complications in the first 30 days than did patients in the local anesthesia and outpatient surgery groups, but no differences in the complication rate were found after 60 days. Visual acuity was similar among these different groups. There were no cases of endophthalmitis. CONCLUSION: Ganciclovir implant surgery in patients with AIDS and cytomegalovirus retinitis was associated with a low risk of serious complications in the first 60 days after surgery. Vitreous hemorrhage was the most commonly observed complication and resolved in all cases.